Suppression of Sleep-Induced Growth Hormone Secretion by Anticholinergic Agent Abolishes Dawn Phenomenon

The dawn phenomenon was evaluated in eight C-peptide-negative type I (insulin-dependent) diabetic patients on two occasions by measuring glucose concentrations every 30 min from 2400 to 0800 h while the subjects were receiving an insulin infusion (0.12 mU·kg⁻¹ · min⁻¹). In random order at 2230 h, they orally received either a sleeping medication alone or with 5.0 mg methscopolamine bromide, an anticholinergic agent. The peak growth hormone (GH) concentrations (ng/ml ± SE) after sleep were markedly inhibited by methscopolamine (4.7 ± 2.6 vs. 23.0 ± 9.2). During the control night, the late (0400–0800 h) glucose response (area under curve but above 0400 h value) was significantly higher (P < .02) than the early (2400–0400 h) glucose response (area under curve but above 2400 h value). After methscopolamine, the early and late glucose responses were virtually identical. The anticholinergic agent did not affect glucagon levels, overnight urinary catecholamine excretion, or the diurnal cortisol concentrations. The total area under the free fatty acid (FFA) curves was significantly (P < .05) reduced by methscopolamine. We conclude that sleep-induced GH secretion may cause the dawn phenomenon by increasing FFA levels. Oral administration of methscopolamine at bedtime is a simple pharmacological approach that could test the clinical importance of the dawn phenomenon.